FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial

The U.S. Food and Drug Administration (FDA) lifted its hold on CRISPR Therapeutics and Vertex Pharmaceuticals' highly anticipated gene-editing trial Wednesday, allowing the first company-backed trial using the CRISPR/Cas9 technology to start in the U.S.

CRISPR (Nasdaq: CRSP) and Vertex (Nasdaq: VRTX) were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May. The trial is…

Source: bizjournals.com Health Care:Biotechnology headlines - October 12, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news